



Prescribing Tip No. 184 Date: 24<sup>th</sup> November 2017

**Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events**

Mirabegron (Betmiga ▼) is a beta 3-adrenoceptor agonist used in the management of urinary frequency, urgency, and incontinence in overactive bladder syndrome.

Mirabegron is RAG rated **GREEN** on the Lancashire Medicines Management Group website (<http://www.lancsmmg.nhs.uk/medicines/mirabegron/>) and for Greater Preston, Chorley & South Ribble CCG's it is restricted to third line use as per NICE TA 290. **Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.**

The MHRA<sup>1</sup> has reported a recent EU-wide review of the latest safety data for mirabegron. This has led to new measures to help reduce the risks of severe hypertension. It is already known that mirabegron can increase blood pressure. However, cases of severe hypertension have been reported, which include hypertensive crisis associated with reports of cerebrovascular and cardiac events (mainly transient ischaemia attack or stroke) — some with a clear temporal relation to mirabegron use.

- **Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; (systolic blood pressure  $\geq 180$  mm Hg or diastolic blood pressure  $\geq 110$  mm Hg, or both). Regular monitoring of blood pressure is important, especially in patients with pre-existing hypertension.**
- **Data are limited regarding use of mirabegron in patients with stage 2 hypertension (i.e. systolic blood pressure  $\geq 160$  mm Hg or diastolic blood pressure  $\geq 100$  mm Hg) and it should therefore be used with caution in this group.**

Advice for prescribers:

- **Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure  $\geq 180$  mm Hg or diastolic blood pressure  $\geq 110$  mm Hg, or both).**
- **Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension**
- **Please report suspected side effects to mirabegron on a [Yellow Card](#)**

Ref. 1 <https://www.gov.uk/drug-safety-update/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events>

To contact the Medicines Optimisation Team please phone 01772 214302